487 related articles for article (PubMed ID: 24249759)
1. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
Ottney A
Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
[TBL] [Abstract][Full Text] [Related]
2. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
Derosa G; Maffioli P
Curr Clin Pharmacol; 2012 Aug; 7(3):214-28. PubMed ID: 22432846
[TBL] [Abstract][Full Text] [Related]
4. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
Madsbad S
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
[TBL] [Abstract][Full Text] [Related]
6. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
7. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
[TBL] [Abstract][Full Text] [Related]
8. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.
Sun F; Yu K; Yang Z; Wu S; Zhang Y; Shi L; Ji L; Zhan S
Exp Diabetes Res; 2012; 2012():230624. PubMed ID: 23365557
[TBL] [Abstract][Full Text] [Related]
9. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
Horowitz M; Aroda VR; Han J; Hardy E; Rayner CK
Diabetes Obes Metab; 2017 May; 19(5):672-681. PubMed ID: 28058769
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
11. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
12. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
13. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
[TBL] [Abstract][Full Text] [Related]
14. Incretin hormones and the satiation signal.
Holst JJ
Int J Obes (Lond); 2013 Sep; 37(9):1161-8. PubMed ID: 23295502
[TBL] [Abstract][Full Text] [Related]
15. Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats.
Sisley S; Smith K; Sandoval DA; Seeley RJ
Peptides; 2014 Aug; 58():1-6. PubMed ID: 24879927
[TBL] [Abstract][Full Text] [Related]
16. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Gallwitz B
Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
[TBL] [Abstract][Full Text] [Related]
18. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]